Follicular Lymphoma Market

DelveInsight's "Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Follicular Lymphoma market report provides current treatment practices, emerging drugs, Follicular Lymphoma market share of the individual therapies, current and forecasted Follicular Lymphoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Follicular Lymphoma market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Follicular Lymphoma Disease Understanding and Treatment Algorithm

The DelveInsight’s Follicular Lymphoma market report gives a thorough understanding of the Follicular Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

 

Follicular Lymphoma Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Follicular Lymphoma.

 

Follicular Lymphoma Treatment

It covers the details of conventional and current medical therapies available in the Follicular Lymphoma market for the treatment of the condition. It also provides Follicular Lymphoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Follicular Lymphoma Epidemiology 

The Follicular Lymphoma epidemiology section provides insights about the historical and current Follicular Lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Follicular Lymphoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Follicular Lymphoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

Country Wise- Follicular Lymphoma Epidemiology

The epidemiology segment also provides the Follicular Lymphoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Follicular Lymphoma Epidemiology Segmentation in the 7MM

  • Total Incident Cases
  • Risk-specific Incident Cases
  • Stage-specific Incident Cases
  • Mutation-specific Incident Cases
  • Refractory/Relapsed Incident Cases
  • Treatable Cases of Follicular Lymphoma

 

Get detailed insights into the historical as well as forecasted epidemiology in the 7MM, at Follicular Lymphoma Epidemiology Insights
 

Follicular Lymphoma Drug Chapters

The drug chapter segment of the Follicular Lymphoma report encloses the detailed analysis of Follicular Lymphoma marketed drugs and late-stage (Phase-III and Phase-II) Follicular Lymphoma pipeline therapies. It also helps to understand the Follicular Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Follicular Lymphoma Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Follicular Lymphoma treatment.

 

Follicular Lymphoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Follicular Lymphoma treatment.

Follicular Lymphoma Market Outlook

The Follicular Lymphoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Follicular Lymphoma market trends by analyzing the impact of current Follicular Lymphoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Follicular Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Follicular Lymphoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Follicular Lymphoma market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Follicular Lymphoma market in 7MM.

 

The United States Market Outlook

This section provides the total Follicular Lymphoma market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total Follicular Lymphoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Market Outlook

The total Follicular Lymphoma market size and market size by therapies in Japan is also mentioned.

Follicular Lymphoma Drugs Uptake

This section focuses on the rate of uptake of the potential Follicular Lymphoma drugs recently launched in the Follicular Lymphoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Follicular Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Follicular Lymphoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Follicular Lymphoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Follicular Lymphoma Pipeline Development Activities

The Follicular Lymphoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Follicular Lymphoma key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Follicular Lymphoma report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Follicular Lymphoma emerging therapies.

Key Follicular Lymphoma Companies

  • Novartis Pharmaceuticals
  • Xynomic Pharmaceuticals
  • MEI Pharma
  • Epizyme
  • TG Therapeutics
  • Innovent Biologics, and others

Follicular Lymphoma Emerging Therapies

  • Tazverik (Tazemetostat)
  • Kymriah (tisagenlecleucel)
  • Abexinostat
  • Zandelisib (ME-401)
  • Parsaclisib (IBI376), and many more

 

Get detailed insights into the emerging therapies and key companies working in the therapeutic domain, at Follicular Lymphoma Pipeline Insight
 

Reimbursement Scenario in Follicular Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Follicular Lymphoma market trends, we take KOLs and SMEs ' opinion working in the Follicular Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Follicular Lymphoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Follicular Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Follicular Lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Follicular Lymphoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Follicular Lymphoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Follicular Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Follicular Lymphoma market

Report Highlights

  • In the coming years, the Follicular Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Follicular Lymphoma. The launch of emerging therapies will significantly impact the Follicular Lymphoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Follicular Lymphoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Follicular Lymphoma Report Insights

  • Follicular Lymphoma Patient Population
  • Therapeutic Approaches
  • Follicular Lymphoma Pipeline Analysis
  • Follicular Lymphoma Market Size and Trends
  • Follicular Lymphoma Market Opportunities
  • Impact of upcoming Follicular Lymphoma Therapies

Follicular Lymphoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Follicular Lymphoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Follicular Lymphoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Follicular Lymphoma Pipeline Product Profiles
  • Follicular Lymphoma Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Follicular Lymphoma drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Follicular Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Follicular Lymphoma market size during the forecast period (2019-2032)?
  • At what CAGR, the Follicular Lymphoma market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Follicular Lymphoma market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Follicular Lymphoma market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Follicular Lymphoma?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Follicular Lymphoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Follicular Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Follicular Lymphoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Follicular Lymphoma during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Follicular Lymphoma treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Follicular Lymphoma in the USA, Europe, and Japan?
  • What are the Follicular Lymphoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Follicular Lymphoma?
  • How many therapies are in-development by each company for Follicular Lymphoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Follicular Lymphoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Follicular Lymphoma and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Follicular Lymphoma?
  • What are the global historical and forecasted market of Follicular Lymphoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Follicular Lymphoma market
  • To understand the future market competition in the Follicular Lymphoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Follicular Lymphoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Follicular Lymphoma market
  • To understand the future market competition in the Follicular Lymphoma market

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. Competitive Intelligence Analysis for Follicular Lymphoma

4. Follicular Lymphoma: Market Overview at a Glance

4.1. Follicular Lymphoma Total Market Share (%) Distribution in 2019

4.2. Follicular Lymphoma Total Market Share (%) Distribution in 2032

5. Follicular Lymphoma: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Follicular Lymphoma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Follicular Lymphoma Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Follicular Lymphoma Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Follicular Lymphoma Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Follicular Lymphoma Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Follicular Lymphoma Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Follicular Lymphoma Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Follicular Lymphoma Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Follicular Lymphoma Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Follicular Lymphoma Treatment and Management

8.2. Follicular Lymphoma Treatment Algorithm

9. Follicular Lymphoma Unmet Needs

10. Key Endpoints of Follicular Lymphoma Treatment

11. Follicular Lymphoma Marketed Products

11.1. List of Follicular Lymphoma Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Follicular Lymphoma Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Follicular Lymphoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Follicular Lymphoma Market Size in 7MM

13.3. Follicular Lymphoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Follicular Lymphoma Total Market Size in the United States

15.1.2. Follicular Lymphoma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Follicular Lymphoma Total Market Size in Germany

15.3.2. Follicular Lymphoma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Follicular Lymphoma Total Market Size in France

15.4.2. Follicular Lymphoma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Follicular Lymphoma Total Market Size in Italy

15.5.2. Follicular Lymphoma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Follicular Lymphoma Total Market Size in Spain

15.6.2. Follicular Lymphoma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Follicular Lymphoma Total Market Size in the United Kingdom

15.7.2. Follicular Lymphoma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Follicular Lymphoma Total Market Size in Japan

15.8.3. Follicular Lymphoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Follicular Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Follicular Lymphoma Epidemiology (2019-2032)

Table 2: 7MM Follicular Lymphoma Diagnosed and Treatable Cases (2019-2032)

Table 3: Follicular Lymphoma Epidemiology in the United States (2019-2032)

Table 4: Follicular Lymphoma Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Follicular Lymphoma Epidemiology in Germany (2019-2032)

Table 6: Follicular Lymphoma Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Follicular Lymphoma Epidemiology in France (2019-2032)

Table 8: Follicular Lymphoma Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Follicular Lymphoma Epidemiology in Italy (2019-2032)

Table 10: Follicular Lymphoma Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Follicular Lymphoma Epidemiology in Spain (2019-2032)

Table 12: Follicular Lymphoma Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Follicular Lymphoma Epidemiology in the UK (2019-2032)

Table 14: Follicular Lymphoma Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Follicular Lymphoma Epidemiology in Japan (2019-2032)

Table 16: Follicular Lymphoma Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Follicular Lymphoma Epidemiology (2019-2032)

Figure 2: 7MM Follicular Lymphoma Diagnosed and Treatable Cases (2019-2032)

Figure 3: Follicular Lymphoma Epidemiology in the United States (2019-2032)

Figure 4: Follicular Lymphoma Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Follicular Lymphoma Epidemiology in Germany (2019-2032)

Figure 6: Follicular Lymphoma Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Follicular Lymphoma Epidemiology in France (2019-2032)

Figure 8: Follicular Lymphoma Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Follicular Lymphoma Epidemiology in Italy (2019-2032)

Figure 10: Follicular Lymphoma Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Follicular Lymphoma Epidemiology in Spain (2019-2032)

Figure 12: Follicular Lymphoma Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Follicular Lymphoma Epidemiology in the UK (2019-2032)

Figure 14: Follicular Lymphoma Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Follicular Lymphoma Epidemiology in Japan (2019-2032)

Figure 16: Follicular Lymphoma Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

Epizyme|Eisai
Bayer Healthcare Pharmaceuticals
Verastem Oncology
Gilead Sciences
TG Therapeutics
Bristol-Myers-Squibb
Roche
Incyte Corporation
Bristol Myers Squibb
ADC Therapeutics
MorphoSys
Nordic Nanovector
AbbVie
Regeneron Pharmaceuticals
Janssen Research & Development
Novartis
MEI Pharma
BeiGene

 

Forward to Friend

Need A Quote